Hot Topics · Cross-industry
NIH Funding Policy
Federal research budget shifts affecting academic and government demand.
AI-generated · informational only · not investment advice · verify before relying.
01 · The lede
Intelligence brief
SeventhBiz Intelligence
Refreshed 3h agoNIH funding policy has transitioned from abstract regulatory risk to direct revenue constraint across instrumentation, research services, and academic-dependent software businesses in a single reporting cycle. TXG, PACB, BIO, ILMN, and TMO all cite materially elongated sales cycles and suppressed customer purchasing directly tied to NIH's 15% outlay decline in Q3 2026 and the shift to multi-year upfront grant funding.…
The full brief is part of the subscription
03 · Companies
Companies engaging with this topic
Tracked companies with an on-record signal on NIH Funding Policy this cycle.
06 · Evidence
Recent mentions
Preview“mRNA-1469 has been recommended to advance into a Phase 2/3 efficacy study in the Democratic Republic of Congo (DRC), supported by encouraging preclinical and Phase 1 clinical data.”
Additional Program Developments — Infectious Disease Vaccines
“the NIH issued substantially fewer new awards in fiscal year 2026 than in prior years as a result of policies requiring multi-year, up-front funding of certain grants, additional review of awards and other changes to the grant-making process”
Part II Item 1A — Risk Factors
“cuts in Medicaid and research funding... certain sales cycles have elongated and some opportunities, such as opportunities in Life Sciences, have pushed, which negatively impacted our 2025 and 2026 bookings achievement”
MD&A — Macroeconomic Environment and Strategic Operating Plan
Unlock NIH Funding Policy
The full intelligence brief, how the language shifted quarter over quarter, the bear case, and every company mention — verbatim and source-cited.